Cognition Therapeutics’ (CGTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock.

Several other brokerages have also weighed in on CGTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cognition Therapeutics in a report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday, August 8th. Finally, Wall Street Zen raised Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cognition Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Stock Performance

Shares of CGTX opened at $1.39 on Wednesday. The firm has a market cap of $122.70 million, a PE ratio of -2.90 and a beta of 1.23. Cognition Therapeutics has a 52-week low of $0.22 and a 52-week high of $3.83. The business’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $1.15.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Research analysts predict that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter worth about $138,000. Millennium Management LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter worth approximately $757,000. Chescapmanager LLC raised its stake in shares of Cognition Therapeutics by 98.1% in the third quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock worth $1,346,000 after purchasing an additional 493,770 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Cognition Therapeutics by 34.7% in the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after purchasing an additional 7,641 shares in the last quarter. Finally, Private Management Group Inc. purchased a new position in shares of Cognition Therapeutics during the third quarter valued at approximately $32,000. 43.35% of the stock is owned by institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.